Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Aspirin for Primary Prevention of Cardiovascular Diseases: Current Concepts, Unanswered Questions and Future Directions.

Castro-Torres Y, Katholi RE, Yar Khan N.

Hellenic J Cardiol. 2015 Nov-Dec;56(6):461-74. No abstract available.

2.

Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice.

Castro-Torres Y, Carmona-Puerta R, Katholi RE.

World J Clin Cases. 2015 Aug 16;3(8):705-20. doi: 10.12998/wjcc.v3.i8.705. Review.

3.

Natriuretic peptides, obesity and cardiovascular diseases.

Castro-Torres Y, Katholi RE.

Rev Assoc Med Bras (1992). 2015 Jan-Feb;61(1):19-20. doi: 10.1590/1806-9282.61.01.019. Erratum in: Rev Assoc Med Bras (1992). 2015 May-Jun;61(3):290. Torres, Yaniel Castro [corrected to Castro-Torres, Yaniel].

4.

Renal denervation with vincristine for the treatment of resistant hypertension: further investigations are needed to implement it globally.

Castro Torres Y, Katholi RE.

Hellenic J Cardiol. 2014 Nov-Dec;55(6):514-5. No abstract available.

5.

Novel treatment approaches in hypertensive type 2 diabetic patients.

Castro Torres Y, Katholi RE.

World J Diabetes. 2014 Aug 15;5(4):536-45. doi: 10.4239/wjd.v5.i4.536. Review.

6.

Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel on Renal Sympathetic Denervation.

Angle JF, Prince EA, Matsumoto AH, Lohmeier TE, Roberts AM, Misra S, Razavi MK, Katholi RE, Sarin SN, Sica DA, Shivkumar K, Ahrar K.

J Vasc Interv Radiol. 2014 Apr;25(4):497-509. doi: 10.1016/j.jvir.2013.12.572. Review. No abstract available.

PMID:
24674208
7.

Renal denervation for treating resistant hypertension: current evidence and future insights from a global perspective.

Castro Torres Y, Katholi RE.

Int J Hypertens. 2013;2013:513214. doi: 10.1155/2013/513214. Review.

8.

Renal sympathetic denervation for treatment-resistant hypertension…in moderation.

Rocha-Singh KJ, Katholi RE.

J Am Coll Cardiol. 2013 Nov 12;62(20):1887-9. doi: 10.1016/j.jacc.2013.06.020. No abstract available.

9.
10.

Catheter-based renal sympathetic denervation reduces systolic blood pressure by 32 mm Hg in people with treatment-resistant hypertension.

Katholi RE, Rocha-Singh KJ.

Evid Based Med. 2011 Aug;16(4):109-10. doi: 10.1136/ebm1194. No abstract available.

PMID:
21377980
11.

Renal nerves in the maintenance of hypertension: a potential therapeutic target.

Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA.

Curr Hypertens Rep. 2010 Jun;12(3):196-204. doi: 10.1007/s11906-010-0108-4. Review.

PMID:
20424950
12.

The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance?

Katholi RE, Rocha-Singh KJ.

Prog Cardiovasc Dis. 2009 Nov-Dec;52(3):243-8. doi: 10.1016/j.pcad.2009.09.003. Review.

PMID:
19917336
13.

Contrast-induced nephropathy-choice of contrast agents to reduce renal risk.

Katholi RE.

Am Heart Hosp J. 2009 Summer;7(1):45-9. Review.

PMID:
19742433
14.

Contrast-induced nephropathy and long-term adverse events: cause and effect?

Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, Sharma SK, Labinaz M, Gelormini JL, Barrett BJ.

Clin J Am Soc Nephrol. 2009 Jul;4(7):1162-9. doi: 10.2215/CJN.00550109.

15.

N-Acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study.

Staniloae CS, Doucet S, Sharma SK, Katholi RE, Mody KR, Coppola JT, Solomon R.

J Interv Cardiol. 2009 Jun;22(3):261-5. doi: 10.1111/j.1540-8183.2009.00456.x.

PMID:
19490358
16.

Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study.

Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Bakris GL; GEMINI Investigators..

J Cardiometab Syndr. 2008 Fall;3(4):211-7. doi: 10.1111/j.1559-4572.2008.00017.x.

17.

Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography.

Hardiek KJ, Katholi RE, Robbs RS, Katholi CE.

J Diabetes Complications. 2008 May-Jun;22(3):171-7. doi: 10.1016/j.jdiacomp.2006.11.002.

PMID:
18413220
18.

Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.

Wright JT Jr, Bakris GL, Bell DS, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Holdbrook FK, Lukas MA, Iyengar M.

J Clin Hypertens (Greenwich). 2007 Nov;9(11):842-9.

19.

Body weight changes with beta-blocker use: results from GEMINI.

Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT Jr, Bangalore S, Holdbrook FK, Lukas MA, Anderson KM, Bakris GL; GEMINI Investigators..

Am J Med. 2007 Jul;120(7):610-5.

PMID:
17602935
20.

Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.

Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE; Investigators of the CARE Study..

Circulation. 2007 Jun 26;115(25):3189-96.

Items per page

Supplemental Content

Loading ...
Support Center